Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 204 entries
Sorted by: Best Match Show Resources per page
Candidate serum metabolite biomarkers for differentiating gastroesophageal reflux disease, Barrett's esophagus, and high-grade dysplasia/esophageal adenocarcinoma.

Metabolomics : Official journal of the Metabolomic Society

Buas MF, Gu H, Djukovic D, Zhu J, Onstad L, Reid BJ, Raftery D, Vaughan TL.
PMID: 28190989
Metabolomics. 2017 Mar;13(3). doi: 10.1007/s11306-016-1154-y. Epub 2017 Jan 20.

INTRODUCTION/OBJECTIVES: Incidence of esophageal adenocarcinoma (EA), an often fatal cancer, has increased sharply over recent decades. Several important risk factors (reflux, obesity, smoking) have been identified for EA and its precursor, Barrett's esophagus (BE), but a key challenge remains...

Cite
Buas MF, Gu H, Djukovic D, et al. Candidate serum metabolite biomarkers for differentiating gastroesophageal reflux disease, Barrett's esophagus, and high-grade dysplasia/esophageal adenocarcinoma. Metabolomics. 2017;13(3)doi: 10.1007/s11306-016-1154-y.
Buas, M. F., Gu, H., Djukovic, D., Zhu, J., Onstad, L., Reid, B. J., Raftery, D., & Vaughan, T. L. (2017). Candidate serum metabolite biomarkers for differentiating gastroesophageal reflux disease, Barrett's esophagus, and high-grade dysplasia/esophageal adenocarcinoma. Metabolomics : Official journal of the Metabolomic Society, 13(3), . https://doi.org/10.1007/s11306-016-1154-y
Buas, Matthew F, et al. "Candidate serum metabolite biomarkers for differentiating gastroesophageal reflux disease, Barrett's esophagus, and high-grade dysplasia/esophageal adenocarcinoma." Metabolomics : Official journal of the Metabolomic Society vol. 13,3 (2017). doi: https://doi.org/10.1007/s11306-016-1154-y
Buas MF, Gu H, Djukovic D, Zhu J, Onstad L, Reid BJ, Raftery D, Vaughan TL. Candidate serum metabolite biomarkers for differentiating gastroesophageal reflux disease, Barrett's esophagus, and high-grade dysplasia/esophageal adenocarcinoma. Metabolomics. 2017 Mar;13(3). doi: 10.1007/s11306-016-1154-y. Epub 2017 Jan 20. PMID: 28190989; PMCID: PMC5295138.
Copy Download .nbib Format: NLM
A randomized safety and pharmacokinetic trial of daily tenofovir 1% gel in term and near-term pregnancy.

Journal of the International AIDS Society

Beigi RH, Noguchi LM, Montgomery E, Biggio J, Hendrix CW, Marzinke MA, Dai JY, Pan J, Kunjara Na Ayudhya R, Schwartz JL, Isaacs K, Piper JM, Watts DH.
PMID: 27658440
J Int AIDS Soc. 2016 Sep 21;19(1):20990. doi: 10.7448/IAS.19.1.20990. eCollection 2016.

INTRODUCTION: Vaginal tenofovir (TFV) 1% gel may reduce incident HIV-1 and herpes simplex virus 2 infection. Pregnancy may increase risk of HIV acquisition, and incident HIV in pregnancy potentiates perinatal HIV transmission. Our objective was to investigate the safety...

Cite
Beigi RH, Noguchi LM, Montgomery E, et al. A randomized safety and pharmacokinetic trial of daily tenofovir 1% gel in term and near-term pregnancy. J Int AIDS Soc. 2016;19(1):20990doi: 10.7448/IAS.19.1.20990.
Beigi, R. H., Noguchi, L. M., Montgomery, E., Biggio, J., Hendrix, C. W., Marzinke, M. A., Dai, J. Y., Pan, J., Kunjara Na Ayudhya, R., Schwartz, J. L., Isaacs, K., Piper, J. M., & Watts, D. H. (2016). A randomized safety and pharmacokinetic trial of daily tenofovir 1% gel in term and near-term pregnancy. Journal of the International AIDS Society, 19(1), 20990. https://doi.org/10.7448/IAS.19.1.20990
Beigi, Richard H, et al. "A randomized safety and pharmacokinetic trial of daily tenofovir 1% gel in term and near-term pregnancy." Journal of the International AIDS Society vol. 19,1 (2016): 20990. doi: https://doi.org/10.7448/IAS.19.1.20990
Beigi RH, Noguchi LM, Montgomery E, Biggio J, Hendrix CW, Marzinke MA, Dai JY, Pan J, Kunjara Na Ayudhya R, Schwartz JL, Isaacs K, Piper JM, Watts DH. A randomized safety and pharmacokinetic trial of daily tenofovir 1% gel in term and near-term pregnancy. J Int AIDS Soc. 2016 Sep 21;19(1):20990. doi: 10.7448/IAS.19.1.20990. eCollection 2016. PMID: 27658440; PMCID: PMC5034095.
Copy Download .nbib Format: NLM
High-throughput sequencing of the B-cell receptor in African Burkitt lymphoma reveals clues to pathogenesis.

Blood advances

Lombardo KA, Coffey DG, Morales AJ, Carlson CS, Towlerton AMH, Gerdts SE, Nkrumah FK, Neequaye J, Biggar RJ, Orem J, Casper C, Mbulaiteye SM, Bhatia KG, Warren EH.
PMID: 29296973
Blood Adv. 2017 Mar 21;1(9):535-544. doi: 10.1182/bloodadvances.2016000794. eCollection 2017 Mar 28.

Burkitt lymphoma (BL), the most common pediatric cancer in sub-Saharan Africa, is a malignancy of antigen-experienced B lymphocytes. High-throughput sequencing (HTS) of the immunoglobulin heavy (

Cite
Lombardo KA, Coffey DG, Morales AJ, et al. High-throughput sequencing of the B-cell receptor in African Burkitt lymphoma reveals clues to pathogenesis. Blood Adv. 2017;1(9):535-544doi: 10.1182/bloodadvances.2016000794.
Lombardo, K. A., Coffey, D. G., Morales, A. J., Carlson, C. S., Towlerton, A. M. H., Gerdts, S. E., Nkrumah, F. K., Neequaye, J., Biggar, R. J., Orem, J., Casper, C., Mbulaiteye, S. M., Bhatia, K. G., & Warren, E. H. (2017). High-throughput sequencing of the B-cell receptor in African Burkitt lymphoma reveals clues to pathogenesis. Blood advances, 1(9), 535-544. https://doi.org/10.1182/bloodadvances.2016000794
Lombardo, Katharine A, et al. "High-throughput sequencing of the B-cell receptor in African Burkitt lymphoma reveals clues to pathogenesis." Blood advances vol. 1,9 (2017): 535-544. doi: https://doi.org/10.1182/bloodadvances.2016000794
Lombardo KA, Coffey DG, Morales AJ, Carlson CS, Towlerton AMH, Gerdts SE, Nkrumah FK, Neequaye J, Biggar RJ, Orem J, Casper C, Mbulaiteye SM, Bhatia KG, Warren EH. High-throughput sequencing of the B-cell receptor in African Burkitt lymphoma reveals clues to pathogenesis. Blood Adv. 2017 Mar 21;1(9):535-544. doi: 10.1182/bloodadvances.2016000794. eCollection 2017 Mar 28. PMID: 29296973; PMCID: PMC5728594.
Copy Download .nbib Format: NLM
Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Wang X, Su YR, Petersen PS, Bien S, Schmit SL, Drew DA, Albanes D, Berndt SI, Brenner H, Campbell PT, Casey G, Chang-Claude J, Gallinger SJ, Gruber SB, Haile RW, Harrison TA, Hoffmeister M, Jacobs EJ, Jenkins MA, Joshi AD, Li L, Lin Y, Lindor NM, Marchand LL, Martin V, Milne R, Maclnnis R, Moreno V, Nan H, Newcomb PA, Potter JD, Rennert G, Rennert H, Slattery ML, Thibodeau SN, Weinstein SJ, Woods MO, Chan AT, White E, Hsu L, Peters U.
PMID: 32651213
Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1800-1808. doi: 10.1158/1055-9965.EPI-19-1018. Epub 2020 Jul 10.

BACKGROUND: Regular use of nonsteroidal anti-inflammatory drugs (NSAID) is associated with lower risk of colorectal cancer. Genome-wide interaction analysis on single variants (G × E) has identified several SNPs that may interact with NSAIDs to confer colorectal cancer risk,...

Cite
Wang X, Su YR, Petersen PS, et al. Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2020;29(9):1800-1808doi: 10.1158/1055-9965.EPI-19-1018.
Wang, X., Su, Y. R., Petersen, P. S., Bien, S., Schmit, S. L., Drew, D. A., Albanes, D., Berndt, S. I., Brenner, H., Campbell, P. T., Casey, G., Chang-Claude, J., Gallinger, S. J., Gruber, S. B., Haile, R. W., Harrison, T. A., Hoffmeister, M., Jacobs, E. J., Jenkins, M. A., Joshi, A. D., Li, L., Lin, Y., Lindor, N. M., Marchand, L. L., Martin, V., Milne, R., Maclnnis, R., Moreno, V., Nan, H., Newcomb, P. A., Potter, J. D., Rennert, G., Rennert, H., Slattery, M. L., Thibodeau, S. N., Weinstein, S. J., Woods, M. O., Chan, A. T., White, E., Hsu, L., & Peters, U. (2020). Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 29(9), 1800-1808. https://doi.org/10.1158/1055-9965.EPI-19-1018
Wang, Xiaoliang, et al. "Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 29,9 (2020): 1800-1808. doi: https://doi.org/10.1158/1055-9965.EPI-19-1018
Wang X, Su YR, Petersen PS, Bien S, Schmit SL, Drew DA, Albanes D, Berndt SI, Brenner H, Campbell PT, Casey G, Chang-Claude J, Gallinger SJ, Gruber SB, Haile RW, Harrison TA, Hoffmeister M, Jacobs EJ, Jenkins MA, Joshi AD, Li L, Lin Y, Lindor NM, Marchand LL, Martin V, Milne R, Maclnnis R, Moreno V, Nan H, Newcomb PA, Potter JD, Rennert G, Rennert H, Slattery ML, Thibodeau SN, Weinstein SJ, Woods MO, Chan AT, White E, Hsu L, Peters U. Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1800-1808. doi: 10.1158/1055-9965.EPI-19-1018. Epub 2020 Jul 10. PMID: 32651213; PMCID: PMC7556991.
Copy Download .nbib Format: NLM
Genetic architectures of proximal and distal colorectal cancer are partly distinct.

Gut

Huyghe JR, Harrison TA, Bien SA, Hampel H, Figueiredo JC, Schmit SL, Conti DV, Chen S, Qu C, Lin Y, Barfield R, Baron JA, Cross AJ, Diergaarde B, Duggan D, Harlid S, Imaz L, Kang HM, Levine DM, Perduca V, Perez-Cornago A, Sakoda LC, Schumacher FR, Slattery ML, Toland AE, van Duijnhoven FJB, Van Guelpen B, Agudo A, Albanes D, Alonso MH, Anderson K, Arnau-Collell C, Arndt V, Banbury BL, Bassik MC, Berndt SI, Bézieau S, Bishop DT, Boehm J, Boeing H, Boutron-Ruault MC, Brenner H, Brezina S, Buch S, Buchanan DD, Burnett-Hartman A, Caan BJ, Campbell PT, Carr PR, Castells A, Castellví-Bel S, Chan AT, Chang-Claude J, Chanock SJ, Curtis KR, de la Chapelle A, Easton DF, English DR, Feskens EJM, Gala M, Gallinger SJ, Gauderman WJ, Giles GG, Goodman PJ, Grady WM, Grove JS, Gsur A, Gunter MJ, Haile RW, Hampe J, Hoffmeister M, Hopper JL, Hsu WL, Huang WY, Hudson TJ, Jenab M, Jenkins MA, Joshi AD, Keku TO, Kooperberg C, Kühn T, Küry S, Le Marchand L, Lejbkowicz F, Li CI, Li L, Lieb W, Lindblom A, Lindor NM, Männistö S, Markowitz SD, Milne RL, Moreno L, Murphy N, Nassir R, Offit K, Ogino S, Panico S, Parfrey PS, Pearlman R, Pharoah PDP, Phipps AI, Platz EA, Potter JD, Prentice RL, Qi L, Raskin L, Rennert G, Rennert HS, Riboli E, Schafmayer C, Schoen RE, Seminara D, Song M, Su YR, Tangen CM, Thibodeau SN, Thomas DC, Trichopoulou A, Ulrich CM, Visvanathan K, Vodicka P, Vodickova L, Vymetalkova V, Weigl K, Weinstein SJ, White E, Wolk A, Woods MO, Wu AH, Abecasis GR, Nickerson DA, Scacheri PC, Kundaje A, Casey G, Gruber SB, Hsu L, Moreno V, Hayes RB, Newcomb PA, Peters U.
PMID: 33632709
Gut. 2021 Jul;70(7):1325-1334. doi: 10.1136/gutjnl-2020-321534. Epub 2021 Feb 25.

OBJECTIVE: An understanding of the etiologic heterogeneity of colorectal cancer (CRC) is critical for improving precision prevention, including individualized screening recommendations and the discovery of novel drug targets and repurposable drug candidates for chemoprevention. Known differences in molecular characteristics...

Cite
Huyghe JR, Harrison TA, Bien SA, et al. Genetic architectures of proximal and distal colorectal cancer are partly distinct. Gut. 2021;70(7):1325-1334doi: 10.1136/gutjnl-2020-321534.
Huyghe, J. R., Harrison, T. A., Bien, S. A., Hampel, H., Figueiredo, J. C., Schmit, S. L., Conti, D. V., Chen, S., Qu, C., Lin, Y., Barfield, R., Baron, J. A., Cross, A. J., Diergaarde, B., Duggan, D., Harlid, S., Imaz, L., Kang, H. M., Levine, D. M., Perduca, V., Perez-Cornago, A., Sakoda, L. C., Schumacher, F. R., Slattery, M. L., Toland, A. E., van Duijnhoven, F. J. B., Van Guelpen, B., Agudo, A., Albanes, D., Alonso, M. H., Anderson, K., Arnau-Collell, C., Arndt, V., Banbury, B. L., Bassik, M. C., Berndt, S. I., Bézieau, S., Bishop, D. T., Boehm, J., Boeing, H., Boutron-Ruault, M. C., Brenner, H., Brezina, S., Buch, S., Buchanan, D. D., Burnett-Hartman, A., Caan, B. J., Campbell, P. T., Carr, P. R., Castells, A., Castellví-Bel, S., Chan, A. T., Chang-Claude, J., Chanock, S. J., Curtis, K. R., de la Chapelle, A., Easton, D. F., English, D. R., Feskens, E. J. M., Gala, M., Gallinger, S. J., Gauderman, W. J., Giles, G. G., Goodman, P. J., Grady, W. M., Grove, J. S., Gsur, A., Gunter, M. J., Haile, R. W., Hampe, J., Hoffmeister, M., Hopper, J. L., Hsu, W. L., Huang, W. Y., Hudson, T. J., Jenab, M., Jenkins, M. A., Joshi, A. D., Keku, T. O., Kooperberg, C., Kühn, T., Küry, S., Le Marchand, L., Lejbkowicz, F., Li, C. I., Li, L., Lieb, W., Lindblom, A., Lindor, N. M., Männistö, S., Markowitz, S. D., Milne, R. L., Moreno, L., Murphy, N., Nassir, R., Offit, K., Ogino, S., Panico, S., Parfrey, P. S., Pearlman, R., Pharoah, P. D. P., Phipps, A. I., Platz, E. A., Potter, J. D., Prentice, R. L., Qi, L., Raskin, L., Rennert, G., Rennert, H. S., Riboli, E., Schafmayer, C., Schoen, R. E., Seminara, D., Song, M., Su, Y. R., Tangen, C. M., Thibodeau, S. N., Thomas, D. C., Trichopoulou, A., Ulrich, C. M., Visvanathan, K., Vodicka, P., Vodickova, L., Vymetalkova, V., Weigl, K., Weinstein, S. J., White, E., Wolk, A., Woods, M. O., Wu, A. H., Abecasis, G. R., Nickerson, D. A., Scacheri, P. C., Kundaje, A., Casey, G., Gruber, S. B., Hsu, L., Moreno, V., Hayes, R. B., Newcomb, P. A., & Peters, U. (2021). Genetic architectures of proximal and distal colorectal cancer are partly distinct. Gut, 70(7), 1325-1334. https://doi.org/10.1136/gutjnl-2020-321534
Huyghe, Jeroen R, et al. "Genetic architectures of proximal and distal colorectal cancer are partly distinct." Gut vol. 70,7 (2021): 1325-1334. doi: https://doi.org/10.1136/gutjnl-2020-321534
Huyghe JR, Harrison TA, Bien SA, Hampel H, Figueiredo JC, Schmit SL, Conti DV, Chen S, Qu C, Lin Y, Barfield R, Baron JA, Cross AJ, Diergaarde B, Duggan D, Harlid S, Imaz L, Kang HM, Levine DM, Perduca V, Perez-Cornago A, Sakoda LC, Schumacher FR, Slattery ML, Toland AE, van Duijnhoven FJB, Van Guelpen B, Agudo A, Albanes D, Alonso MH, Anderson K, Arnau-Collell C, Arndt V, Banbury BL, Bassik MC, Berndt SI, Bézieau S, Bishop DT, Boehm J, Boeing H, Boutron-Ruault MC, Brenner H, Brezina S, Buch S, Buchanan DD, Burnett-Hartman A, Caan BJ, Campbell PT, Carr PR, Castells A, Castellví-Bel S, Chan AT, Chang-Claude J, Chanock SJ, Curtis KR, de la Chapelle A, Easton DF, English DR, Feskens EJM, Gala M, Gallinger SJ, Gauderman WJ, Giles GG, Goodman PJ, Grady WM, Grove JS, Gsur A, Gunter MJ, Haile RW, Hampe J, Hoffmeister M, Hopper JL, Hsu WL, Huang WY, Hudson TJ, Jenab M, Jenkins MA, Joshi AD, Keku TO, Kooperberg C, Kühn T, Küry S, Le Marchand L, Lejbkowicz F, Li CI, Li L, Lieb W, Lindblom A, Lindor NM, Männistö S, Markowitz SD, Milne RL, Moreno L, Murphy N, Nassir R, Offit K, Ogino S, Panico S, Parfrey PS, Pearlman R, Pharoah PDP, Phipps AI, Platz EA, Potter JD, Prentice RL, Qi L, Raskin L, Rennert G, Rennert HS, Riboli E, Schafmayer C, Schoen RE, Seminara D, Song M, Su YR, Tangen CM, Thibodeau SN, Thomas DC, Trichopoulou A, Ulrich CM, Visvanathan K, Vodicka P, Vodickova L, Vymetalkova V, Weigl K, Weinstein SJ, White E, Wolk A, Woods MO, Wu AH, Abecasis GR, Nickerson DA, Scacheri PC, Kundaje A, Casey G, Gruber SB, Hsu L, Moreno V, Hayes RB, Newcomb PA, Peters U. Genetic architectures of proximal and distal colorectal cancer are partly distinct. Gut. 2021 Jul;70(7):1325-1334. doi: 10.1136/gutjnl-2020-321534. Epub 2021 Feb 25. PMID: 33632709; PMCID: PMC8223655.
Copy Download .nbib Format: NLM
Re-calibrating pure risk integrating individual data from two-phase studies with external summary statistics.

Biometrics

Zheng J, Zheng Y, Hsu L.
PMID: 34390251
Biometrics. 2021 Aug 13; doi: 10.1111/biom.13543. Epub 2021 Aug 13.

Accurate risk assessment is critical in clinical decision-making. It entails the projected risk based on a risk prediction model agreeing with the observed risk in the target cohort. However, the model often over- or under-estimates the risk. Building a...

Cite
Zheng J, Zheng Y, Hsu L. Re-calibrating pure risk integrating individual data from two-phase studies with external summary statistics. Biometrics. 2021;doi: 10.1111/biom.13543.
Zheng, J., Zheng, Y., & Hsu, L. (2021). Re-calibrating pure risk integrating individual data from two-phase studies with external summary statistics. Biometrics, . https://doi.org/10.1111/biom.13543
Zheng, Jiayin, et al. "Re-calibrating pure risk integrating individual data from two-phase studies with external summary statistics." Biometrics vol. (2021). doi: https://doi.org/10.1111/biom.13543
Zheng J, Zheng Y, Hsu L. Re-calibrating pure risk integrating individual data from two-phase studies with external summary statistics. Biometrics. 2021 Aug 13; doi: 10.1111/biom.13543. Epub 2021 Aug 13. PMID: 34390251.
Copy Download .nbib Format: NLM
Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.

The Prostate

Graham LS, True LD, Gulati R, Schade GR, Wright J, Grivas P, Yezefski T, Nega K, Alexander K, Hou WM, Yu EY, Montgomery B, Mostaghel EA, Matsumoto AA, Marck B, Sharifi N, Ellis WJ, Reder NP, Lin DW, Nelson PS, Schweizer MT.
PMID: 33755225
Prostate. 2021 May;81(7):418-426. doi: 10.1002/pros.24118. Epub 2021 Mar 23.

BACKGROUND: Localized prostate cancers (PCs) may resist neoadjuvant androgen receptor (AR)-targeted therapies as a result of persistent intraprostatic androgens arising through upregulation of steroidogenic enzymes. Therefore, we sought to evaluate clinical effects of neoadjuvant indomethacin (Indo), which inhibits the...

Cite
Graham LS, True LD, Gulati R, et al. Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer. Prostate. 2021;81(7):418-426doi: 10.1002/pros.24118.
Graham, L. S., True, L. D., Gulati, R., Schade, G. R., Wright, J., Grivas, P., Yezefski, T., Nega, K., Alexander, K., Hou, W. M., Yu, E. Y., Montgomery, B., Mostaghel, E. A., Matsumoto, A. A., Marck, B., Sharifi, N., Ellis, W. J., Reder, N. P., Lin, D. W., Nelson, P. S., & Schweizer, M. T. (2021). Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer. The Prostate, 81(7), 418-426. https://doi.org/10.1002/pros.24118
Graham, Laura S, et al. "Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer." The Prostate vol. 81,7 (2021): 418-426. doi: https://doi.org/10.1002/pros.24118
Graham LS, True LD, Gulati R, Schade GR, Wright J, Grivas P, Yezefski T, Nega K, Alexander K, Hou WM, Yu EY, Montgomery B, Mostaghel EA, Matsumoto AA, Marck B, Sharifi N, Ellis WJ, Reder NP, Lin DW, Nelson PS, Schweizer MT. Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer. Prostate. 2021 May;81(7):418-426. doi: 10.1002/pros.24118. Epub 2021 Mar 23. PMID: 33755225; PMCID: PMC8044035.
Copy Download .nbib Format: NLM
Modulation of the Human Pancreatic Ductal Adenocarcinoma Immune Microenvironment by Stereotactic Body Radiotherapy.

Clinical cancer research : an official journal of the American Association for Cancer Research

Mills BN, Qiu H, Drage MG, Chen C, Mathew JS, Garrett-Larsen J, Ye J, Uccello TP, Murphy JD, Belt BA, Lord EM, Katz AW, Linehan DC, Gerber SA.
PMID: 34862242
Clin Cancer Res. 2022 Jan 01;28(1):150-162. doi: 10.1158/1078-0432.CCR-21-2495. Epub 2021 Dec 03.

PURPOSE: Stereotactic body radiotherapy (SBRT) is an emerging treatment modality for pancreatic ductal adenocarcinoma (PDAC), which can effectively prime cytotoxic T cells by inducing immunogenic tumor cell death in preclinical models. SBRT effects on human PDAC have yet to...

Cite
Mills BN, Qiu H, Drage MG, et al. Modulation of the Human Pancreatic Ductal Adenocarcinoma Immune Microenvironment by Stereotactic Body Radiotherapy. Clin Cancer Res. 2021;28(1):150-162doi: 10.1158/1078-0432.CCR-21-2495.
Mills, B. N., Qiu, H., Drage, M. G., Chen, C., Mathew, J. S., Garrett-Larsen, J., Ye, J., Uccello, T. P., Murphy, J. D., Belt, B. A., Lord, E. M., Katz, A. W., Linehan, D. C., & Gerber, S. A. (2022). Modulation of the Human Pancreatic Ductal Adenocarcinoma Immune Microenvironment by Stereotactic Body Radiotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(1), 150-162. https://doi.org/10.1158/1078-0432.CCR-21-2495
Mills, Bradley N, et al. "Modulation of the Human Pancreatic Ductal Adenocarcinoma Immune Microenvironment by Stereotactic Body Radiotherapy." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 28,1 (2022): 150-162. doi: https://doi.org/10.1158/1078-0432.CCR-21-2495
Mills BN, Qiu H, Drage MG, Chen C, Mathew JS, Garrett-Larsen J, Ye J, Uccello TP, Murphy JD, Belt BA, Lord EM, Katz AW, Linehan DC, Gerber SA. Modulation of the Human Pancreatic Ductal Adenocarcinoma Immune Microenvironment by Stereotactic Body Radiotherapy. Clin Cancer Res. 2022 Jan 01;28(1):150-162. doi: 10.1158/1078-0432.CCR-21-2495. Epub 2021 Dec 03. PMID: 34862242; PMCID: PMC8738140.
Copy Download .nbib Format: NLM
Genetic variants associated with cytomegalovirus infection after allogeneic hematopoietic cell transplantation.

Blood

Casto AM, Seo S, Levine DM, Storer BE, Dong X, Hansen JA, Boeckh M, Martin PJ.
PMID: 34269803
Blood. 2021 Oct 28;138(17):1628-1636. doi: 10.1182/blood.2021012153.

Human cytomegalovirus (CMV) reactivation is a frequent complication of allogeneic hematopoietic cell transplantation (HCT). Despite routine screening for CMV reactivation and early antiviral treatment, the rates of CMV-related complications after HCT remain high. Genetic variants in both the donor...

Cite
Casto AM, Seo S, Levine DM, et al. Genetic variants associated with cytomegalovirus infection after allogeneic hematopoietic cell transplantation. Blood. 2021;138(17):1628-1636doi: 10.1182/blood.2021012153.
Casto, A. M., Seo, S., Levine, D. M., Storer, B. E., Dong, X., Hansen, J. A., Boeckh, M., & Martin, P. J. (2021). Genetic variants associated with cytomegalovirus infection after allogeneic hematopoietic cell transplantation. Blood, 138(17), 1628-1636. https://doi.org/10.1182/blood.2021012153
Casto, Amanda M, et al. "Genetic variants associated with cytomegalovirus infection after allogeneic hematopoietic cell transplantation." Blood vol. 138,17 (2021): 1628-1636. doi: https://doi.org/10.1182/blood.2021012153
Casto AM, Seo S, Levine DM, Storer BE, Dong X, Hansen JA, Boeckh M, Martin PJ. Genetic variants associated with cytomegalovirus infection after allogeneic hematopoietic cell transplantation. Blood. 2021 Oct 28;138(17):1628-1636. doi: 10.1182/blood.2021012153. PMID: 34269803; PMCID: PMC8554648.
Copy Download .nbib Format: NLM
Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.

JCI insight

Brennen WN, Zhu Y, Coleman IM, Dalrymple SL, Antony L, Patel RA, Hanratty B, Chikarmane R, Meeker AK, Zheng SL, Hooper JE, Luo J, De Marzo AM, Corey E, Xu J, Yegnasubramanian S, Haffner MC, Nelson PS, Nelson WG, Isaacs WB, Isaacs JT.
PMID: 33724955
JCI Insight. 2021 Apr 22;6(8). doi: 10.1172/jci.insight.146827.

Resistance to AR signaling inhibitors (ARSis) in a subset of metastatic castration-resistant prostate cancers (mCRPCs) occurs with the emergence of AR- neuroendocrine prostate cancer (NEPC) coupled with mutations/deletions in PTEN, TP53, and RB1 and the overexpression of DNMTs, EZH2,...

Cite
Brennen WN, Zhu Y, Coleman IM, et al. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. JCI Insight. 2021;6(8)doi: 10.1172/jci.insight.146827.
Brennen, W. N., Zhu, Y., Coleman, I. M., Dalrymple, S. L., Antony, L., Patel, R. A., Hanratty, B., Chikarmane, R., Meeker, A. K., Zheng, S. L., Hooper, J. E., Luo, J., De Marzo, A. M., Corey, E., Xu, J., Yegnasubramanian, S., Haffner, M. C., Nelson, P. S., Nelson, W. G., Isaacs, W. B., & Isaacs, J. T. (2021). Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. JCI insight, 6(8), . https://doi.org/10.1172/jci.insight.146827
Brennen, W Nathaniel, et al. "Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer." JCI insight vol. 6,8 (2021). doi: https://doi.org/10.1172/jci.insight.146827
Brennen WN, Zhu Y, Coleman IM, Dalrymple SL, Antony L, Patel RA, Hanratty B, Chikarmane R, Meeker AK, Zheng SL, Hooper JE, Luo J, De Marzo AM, Corey E, Xu J, Yegnasubramanian S, Haffner MC, Nelson PS, Nelson WG, Isaacs WB, Isaacs JT. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. JCI Insight. 2021 Apr 22;6(8). doi: 10.1172/jci.insight.146827. PMID: 33724955; PMCID: PMC8119192.
Copy Download .nbib Format: NLM
The glucose-sensing transcription factor MLX balances metabolism and stress to suppress apoptosis and maintain spermatogenesis.

PLoS biology

Carroll PA, Freie BW, Cheng PF, Kasinathan S, Gu H, Hedrich T, Dowdle JA, Venkataramani V, Ramani V, Wu X, Raftery D, Shendure J, Ayer DE, Muller CH, Eisenman RN.
PMID: 34669700
PLoS Biol. 2021 Oct 20;19(10):e3001085. doi: 10.1371/journal.pbio.3001085. eCollection 2021 Oct.

Male germ cell (GC) production is a metabolically driven and apoptosis-prone process. Here, we show that the glucose-sensing transcription factor (TF) MAX-Like protein X (MLX) and its binding partner MondoA are both required for male fertility in the mouse,...

Cite
Carroll PA, Freie BW, Cheng PF, et al. The glucose-sensing transcription factor MLX balances metabolism and stress to suppress apoptosis and maintain spermatogenesis. PLoS Biol. 2021;19(10):e3001085doi: 10.1371/journal.pbio.3001085.
Carroll, P. A., Freie, B. W., Cheng, P. F., Kasinathan, S., Gu, H., Hedrich, T., Dowdle, J. A., Venkataramani, V., Ramani, V., Wu, X., Raftery, D., Shendure, J., Ayer, D. E., Muller, C. H., & Eisenman, R. N. (2021). The glucose-sensing transcription factor MLX balances metabolism and stress to suppress apoptosis and maintain spermatogenesis. PLoS biology, 19(10), e3001085. https://doi.org/10.1371/journal.pbio.3001085
Carroll, Patrick A, et al. "The glucose-sensing transcription factor MLX balances metabolism and stress to suppress apoptosis and maintain spermatogenesis." PLoS biology vol. 19,10 (2021): e3001085. doi: https://doi.org/10.1371/journal.pbio.3001085
Carroll PA, Freie BW, Cheng PF, Kasinathan S, Gu H, Hedrich T, Dowdle JA, Venkataramani V, Ramani V, Wu X, Raftery D, Shendure J, Ayer DE, Muller CH, Eisenman RN. The glucose-sensing transcription factor MLX balances metabolism and stress to suppress apoptosis and maintain spermatogenesis. PLoS Biol. 2021 Oct 20;19(10):e3001085. doi: 10.1371/journal.pbio.3001085. eCollection 2021 Oct. PMID: 34669700; PMCID: PMC8528285.
Copy Download .nbib Format: NLM
Formation of sodium cluster ions complicates liquid chromatography-mass spectrometry metabolomics analyses.

Rapid communications in mass spectrometry : RCM

Carnevale Neto F, Pascua V, Raftery D, Gee JP.
PMID: 34342915
Rapid Commun Mass Spectrom. 2021 Oct 30;35(20):e9175. doi: 10.1002/rcm.9175.

No abstract available.

Cite
Carnevale Neto F, Pascua V, Raftery D, et al. Formation of sodium cluster ions complicates liquid chromatography-mass spectrometry metabolomics analyses. Rapid Commun Mass Spectrom. 2021;35(20):e9175doi: 10.1002/rcm.9175.
Carnevale Neto, F., Pascua, V., Raftery, D., & Gee, J. P. (2021). Formation of sodium cluster ions complicates liquid chromatography-mass spectrometry metabolomics analyses. Rapid communications in mass spectrometry : RCM, 35(20), e9175. https://doi.org/10.1002/rcm.9175
Carnevale Neto, Fausto, et al. "Formation of sodium cluster ions complicates liquid chromatography-mass spectrometry metabolomics analyses." Rapid communications in mass spectrometry : RCM vol. 35,20 (2021): e9175. doi: https://doi.org/10.1002/rcm.9175
Carnevale Neto F, Pascua V, Raftery D, Gee JP. Formation of sodium cluster ions complicates liquid chromatography-mass spectrometry metabolomics analyses. Rapid Commun Mass Spectrom. 2021 Oct 30;35(20):e9175. doi: 10.1002/rcm.9175. PMID: 34342915; PMCID: PMC8429085.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 204 entries